Department of Plastic Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Head Neck. 2021 May;43(5):1553-1562. doi: 10.1002/hed.26625. Epub 2021 Feb 4.
The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites.
Patients with IHs treated with oral propranolol were retrospectively reviewed. Outcomes of propranolol therapy for parotid hemangiomas and other IHs were examined. Regression models were conducted to analyze the factors associated with the outcomes for parotid hemangiomas.
Longer treatment duration was needed for parotid hemangiomas (p = 0.012) at a comparable efficacy and relapse rate as those of IHs at other sites. The higher efficacy was associated with early intervention before 4 months of age (OR = 5.2, p = 0.011), while, the lower relapse rate was associated with adequate treatment duration over 6 months (OR = 9.2, p = 0.010).
With a longer propranolol treatment duration, parotid hemangiomas could achieve a comparable efficacy and relapse rate as other IHs. Early treatment initiation and adequate treatment duration benefited the outcomes.
对于腮腺血管瘤，普萘洛尔治疗的结果仍存在争议，其疗效可能不如其他部位的婴儿血管瘤（IHs）。
回顾性分析接受口服普萘洛尔治疗的 IHs 患者。检查普萘洛尔治疗腮腺血管瘤和其他 IHs 的结果。进行回归模型分析与腮腺血管瘤结果相关的因素。
腮腺血管瘤需要更长的治疗时间（p = 0.012），但其疗效和复发率与其他部位的 IHs 相当。早期干预（<4 个月）与更高的疗效相关（OR = 5.2，p = 0.011），而足够的治疗时间（>6 个月）与更低的复发率相关（OR = 9.2，p = 0.010）。
通过延长普萘洛尔治疗时间，腮腺血管瘤可以达到与其他 IHs 相当的疗效和复发率。早期治疗开始和足够的治疗时间有利于改善结果。
